Perrigo Boosts 2022 Guidance Shifting From Changing Organization To Delivering Results
“We said we would start growing this company ... and this is the year to do it,” says CERO Murray Kessler. With nearly 11% net sales growth for its Americas business leading nearly 10% overall Q1 growth, Perrigo raises full-year guidance for net sales growth to 8% to 9%, up earlier 7% to 8%.
You may also be interested in...
Perrigo is set to welcome a new chief financial officer and corporate security head as it rounds up a fairly successful first quarter.
With Michigan facility closed as cause of bacterial contamination is investigated, FDA announces “has no objection” to Abbott releasing specialty and metabolic formulas “to individuals needing urgent, life-sustaining supplies” on a case-by-case basis.
With Raymond Silcock’s work at Perrigo linked to CEO Murray Kessler’s time with the firm and with the two working together previously as CFO and CEO at a tobacco firm, whether Kessler continues at the helm could become a topic of shareholder interest.